SCHEMBL6152856

SCHEMBL6152856

c1ccc(-c2nccn2CC2CCNCC2)cc1

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 2/20 0.57
ESR1 P03372 1/20 0.48
GABRA1 P14867 1/20 0.44
GABRG2 P18507 1/20 0.44
GABRB3 P28472 1/20 0.44
GABRA5 P31644 1/20 0.44
GABRA3 P34903 1/20 0.44
GABRA2 P47869 1/20 0.44
GBA1 P04062 1/20 0.42
KDM1A O60341 2/20 0.42
AVPR2 P30518 3/20 0.41
AVPR1A P37288 3/20 0.41
MERTK Q12866 1/20 0.41
PLAA Q9Y263 1/20 0.40
EP300 Q09472 1/20 0.40
MELK Q14680 1/20 0.40
ALPG P10696 1/20 0.40
IKBKB O14920 1/20 0.39
CHUK O15111 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1181466 0.78 BRD4 (0.55) BRD4KDM1A
Hydrochloric Acid SCHEMBL28784813 0.77 BRD4 (0.54) BRD4KDM1A
SCHEMBL6039509 0.76 NSD3 (0.43) BRD4GABRA1GABRG2GABRB3GABRA5
SCHEMBL27850097 0.74 ESR1 (0.58) BRD4ESR1PLAAALPG
SCHEMBL5321444 0.73 ESR1 (0.62) BRD4ESR1PLAAALPG
SCHEMBL19924790 0.73 BRD4 (1.00) BRD4
SCHEMBL10844762 0.73 BRD4 (0.39) BRD4GBA1KDM1AAVPR2AVPR1A
SCHEMBL6151661 0.72 KDM4E (0.52)
SCHEMBL29116046 0.72 HTR1A (0.46) BRD4EP300
SCHEMBL27326515 0.72 BRD4 (0.46) BRD4KDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143391-A1 Heterocyclic amides with alpha-4 integrin antagonist activity J. Uriach Y Compañia S.A. (ES) 2005-06-30 US disclosed
EP-1495044-A1 HETEROCYCLIC AMIDES WITH ALPHA-4 INTEGRIN ANTAGONIST ACTIVITY J. Uriach y Compania S.A. (ES) 2005-01-12 EP disclosed
WO-2003084984-A1 HETEROCYCLIC AMIDES WITH ALPHA-4 INTEGRIN ANTAGONIST ACTIVITY J. URIACH Y COMPANIA S.A. (ES) 2003-10-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143391-A1 Heterocyclic amides with alpha-4 integrin antagonist activity ITGB4, ITGA4, ITGA1 BRD4 459/4885ESR1 1508/4885GABRA1 802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.